Sen. Bill Cassidy (R-La.) released a report on Aug. 27, 2026, that critiques the Food and Drug Administration’s handling of the abortion medication mifepristone. The report contends that the FDA has not tightened restrictions on the drug and that the agency’s supervision of companies that manufacture and distribute mifepristone has been inadequate. The STAT article summarizing the release identifies the report as the outcome of a Senate investigation by Cassidy and Republican colleagues on the health committee.
According to the publicly available summary, the report asserts that the FDA continues to redact records related to mifepristone in what Cassidy’s office characterizes as an "unprecedented manner." The report links that practice to diminished transparency and says it has produced unanswered questions about the agency’s oversight.
The STAT piece quotes the report’s claim about redactions and lack of transparency. Beyond that central allegation, the accessible portion of the story does not reproduce the report’s full text or list detailed findings and evidence.
STAT reports that the document is the product of an investigation conducted by Cassidy and other Republicans on the Senate health committee. The investigation examined the compliance practices of Danco, which distributes the brand-name version of mifepristone, and two other companies that manufacture generic versions of the drug.
The article identifies Danco by name but does not provide the names of the two generic manufacturers in the publicly available excerpt. It also does not enumerate specific compliance failures, regulatory violations, or the procedural steps the investigators used to assess the companies.
A focal point of the report is the claim that FDA records related to mifepristone have been redacted extensively. Cassidy’s office frames those redactions as impeding public understanding of regulatory oversight and contributing to unresolved questions, according to the STAT summary.
The STAT article reproduces the report’s language about redactions but does not provide examples of the redacted material, an explanation from the FDA for the redactions, or a sample of the originally requested documents.
STAT characterizes the report as adding to Republican calls for the Trump administration to impose stricter controls on mifepristone. The piece situates the report within broader GOP efforts to press federal regulators on reproductive drug policy.
The publicly available portion of the article does not include a response from the FDA, statements from Danco or the generic manufacturers under investigation, or reactions from Democratic senators or independent experts. STAT identifies Margaret Manto as the Washington correspondent who reported the item.
The STAT summary available without subscription does not contain the full Cassidy report text, nor does it present the specific evidence or examples underpinning the report’s claims. Missing details in the accessible content include:
Because a significant portion of the STAT article and potentially the report itself is behind the outlet’s STAT+ paywall, the accessible source does not permit verification of detailed allegations or the evidence base. Those seeking the full findings, agency responses, and the report’s supporting documents will need to consult the full report or the complete STAT+ article.
Note on sources and limitations
This summary is based solely on the publicly available content of the STAT article dated Aug. 27, 2026. The STAT piece references the Cassidy-led investigation and quotes the report’s claim about redactions, but many substantive elements appear only in the paywalled portion or in the report itself. Where the STAT article did not provide specific facts or documents, this rewrite states that those details were not reported in the accessible source.